Lessons for Providers, MSOs, and Investors
The U.S. Department of Justice’s resolution involving Campus Eye Management provides an early and instructive example of how the Department’s new, department-wide Corporate Enforcement and Voluntary Self-Disclosure Policy may operate in the healthcare sector.
DOJ publicly identified Campus Eye as the first healthcare company receiving a declination under the policy introduced in March 2026. The company voluntarily disclosed alleged misconduct, cooperated with the government’s investigation, and undertook extensive remediation. DOJ declined to prosecute the company, while federal prosecutors separately indicted the former executive alleged to have directed the underlying conduct. Campus Eye also agreed to pay $1 million to compensate victims.
Taken together, those outcomes show that a declination is not the absence of enforcement. It is a differentiated enforcement result, one that rewards corporate conduct after misconduct is discovered while preserving the government’s ability to pursue individuals and address financial harm.
A New Department-Wide Framework for Corporate Enforcement
The March 2026 policy establishes a uniform framework for corporate criminal enforcement across DOJ, except for antitrust matters governed by a separate framework. Its central incentives are straightforward: a company that voluntarily and timely self-discloses misconduct, fully cooperates with the investigation, and timely and appropriately remediates the wrongdoing may receive a declination when aggravating circumstances are absent.
The policy is intended to make the consequences of corporate conduct more predictable. Rather than focusing only on the misconduct itself, DOJ also evaluates how the organization responds after learning of the issue. That response may include preserving and producing relevant information, identifying responsible individuals, addressing the root cause of the conduct, strengthening internal controls, disciplining personnel where appropriate, and compensating victims or returning ill-gotten gains.
For healthcare organizations, this framework is particularly significant. Billing, coding, medical necessity, referral relationships, physician compensation, and management arrangements can create overlapping criminal, civil, regulatory, and financial exposure. The ability to identify and escalate concerns promptly may therefore affect not only whether misconduct continues, but also how the government ultimately treats the organization.
Why Campus Eye Received a Declination
According to DOJ, Campus Eye voluntarily disclosed the alleged misconduct, fully cooperated with investigators, and implemented extensive remediation. The company revised billing, payment, and compensation policies, enhanced monitoring and risk assessment processes, added compliance personnel, and expanded employee training.
Those measures appear to have been central to the outcome. The resolution demonstrates that remediation must be more than a written corrective action plan. DOJ is likely to evaluate whether the organization has changed the policies, people, controls, and incentives that allowed the conduct to occur or remain undetected.
The company’s $1 million payment also underscores an important distinction. A declination can materially reduce the organization’s criminal exposure without eliminating restitution, victim compensation, remediation costs, or other potential consequences. Healthcare organizations should therefore view self-disclosure as part of a broader risk-management and response strategy – not as a mechanism that automatically removes financial exposure.
Individual Accountability Remains a DOJ Priority
While DOJ declined to prosecute Campus Eye, prosecutors announced a seven-count indictment against E. Bruce DiDonato, the founder of the optometry practice and ambulatory surgery center and former chief executive of Campus Eye.
The indictment alleges a long-running scheme involving unnecessary or duplicative diagnostic eye tests, improper referral arrangements, and kickbacks to physicians. Prosecutors allege that, from at least 2015 through March 2023, approximately $3.4 million in fraudulent claims were submitted to Medicare and approximately $1 million was paid. DOJ further alleges that payments to ophthalmologists were concealed through sham consulting agreements and that the financial performance generated through the alleged scheme contributed to Campus Eye’s valuation when the business was later sold to private equity investors.
Though the allegations have not been proven, the parallel outcomes illustrate the two-track approach embedded in DOJ’s policy. Corporate cooperation may improve the organization’s resolution, but it does not protect executives, physicians, employees, or other individuals who are alleged to have directed or participated in misconduct.
Transaction and Valuation Considerations
DOJ’s allegation that financial performance generated through the alleged conduct contributed to Campus Eye’s valuation when the company was sold to private equity also presents a broader transaction-related consideration. Allegations involving improper billing, referral relationships, or physician compensation may raise questions about whether historical financial performance was compliant, reliable, sustainable, and appropriately understood by transaction participants.
The corporate declination does not itself resolve those questions. Nor does it necessarily eliminate potential civil, contractual, payer repayment, or other financial consequences. In addition, remediation measures, such as enhanced compliance personnel, monitoring, policies, and training, may affect the company’s prospective cost structure and operating performance.
The Campus Eye matter therefore reinforces the importance of integrating healthcare regulatory diligence with financial and operational diligence. Investors and healthcare organizations should evaluate not only reported historical performance, but also the compliance practices and underlying business activities supporting that performance. The specific financial or valuation implications, however, would depend on the facts, transaction documents, and financial records applicable to the matter.
Implications for Healthcare Organizations and Investors
The most immediate lesson is that compliance infrastructure can influence both prevention and resolution. Policies governing billing, medical necessity, referral relationships, physician compensation, consulting arrangements, and management services should be supported by monitoring, clear ownership, escalation procedures, and documented follow through. A policy that exists only on paper is unlikely to provide meaningful protection.
Organizations should also establish a response framework before a serious issue arises. That framework should identify who receives allegations, who determines whether counsel should direct an investigation, how potentially relevant records are preserved, when senior leadership or the board is notified, and who has authority to evaluate voluntary disclosure. Delay, fragmented ownership, or an incomplete factual record can narrow the organization’s available options.
For investors and acquirers, the matter highlights the need to connect regulatory diligence with the quality and durability of earnings. Traditional financial diligence may identify unusual growth, margins, utilization, or referral concentration, but those findings may require a healthcare compliance lens to determine what is driving the performance. Likewise, regulatory diligence should be informed by financial and operating data rather than limited to policies, contracts, and interviews.
Post-closing compliance integration is equally important. Acquirers should confirm that billing controls, compensation arrangements, reporting channels, monitoring procedures, and investigation protocols are implemented across the acquired organization. The value of diligence is diminished if identified risks are not tested and remediated after closing.
What the Resolution Means Going Forward
Campus Eye is likely to become an important reference point as DOJ applies its department-wide policy to additional healthcare matters. The resolution shows that voluntary disclosure, cooperation, and meaningful remediation can substantially affect the government’s treatment of a company. It also confirms that a declination does not erase financial consequences, validate historical business practices, or shield individuals from prosecution.
The broader message is that effective compliance programs now serve multiple related purposes. They can prevent misconduct, detect concerns before they become more extensive, and create a credible framework for responding when problems emerge. For providers, MSOs, and investors operating in a highly regulated environment, that response capability is increasingly part of enterprise risk management – not merely a legal function.
Organizations that identify concerns early, establish the facts, preserve decision making flexibility, and implement durable corrective action will be better positioned to manage the legal, operational, financial, and reputational consequences that follow.
Source Materials
- U.S. Department of Justice, Office of Public Affairs. “Fraud Division Resolves Fraud Investigation of Eye Care Group Under New Corporate Enforcement Policy; Health Care Executive Charged for Alleged Fraud and Kickbacks.” Press release no. 26-863, July 29, 2026.
- U.S. Department of Justice. Corporate Enforcement and Voluntary Self-Disclosure Policy. March 10, 2026.
- U.S. Department of Justice, Office of Public Affairs. “Department of Justice Releases First-Ever Corporate Enforcement Policy for All Criminal Cases.” Press release no. 26-230, March 10, 2026.
